Characterization of new nanocomposit PEPC / anthracenehalcon

Nanocomposites PEPC / ANA-Halcon (chemical formula is shown below Figure 1) were investigated. Nanocomposite coatings were obtained by the chemical solution method. PEPC and ANAHalcon were separately dissolved in benzene (Bz) well then strred for mixed not less than 24 hours, then mixed well together and later on, nanocomposite coatings were deposited on optical glass substrates by means of drops and then dried

Energy Transfer in Organic Luminophore Nanocomposites

New light-emitting layers of nanocomposites on polymer base have been obtained. As polymeric matrices the poly-N-vinylpirrolidone has been used. As organic luminophore matertials new compound from izotiocianatopropenone classes 3-(antracen-9-il)-1-(4-izotiocianatofenil)-prop-2-en-1-one (ANA-CH) were utilized. Transparent composite layers were deposited by spin-coating method on glass and quartz substrates. The morphological, optical and photoluminescence properties of the obtained nanocomposites have been investigated. An intensive photoluminescence signal has been identified in green area of the spectrum. His proposed the model of energy transfer in NC from the polymer matrix to ANA-CH luminescence centers. Nanocomposites are proposed for various practical applications

Luminophore organic nanocomposites on the base of polymer and isothiocianatohalconic compounds

The paper presents the results of technology for obtaining nanocomposite thin layers (NC) of organic luminophore compounds (OLC), particularly, those prepared by the sol-gel method

The ongoing pursuit of neuroprotective therapies in Parkinson disease

Many agents developed for neuroprotective treatment of Parkinson disease (PD) have shown great promise in the laboratory, but none have translated to positive results in patients with PD. Potential neuroprotective drugs, such as ubiquinone, creatine and PYM50028, have failed to show any clinical benefits in recent high-profile clinical trials. This 'failure to translate' is likely to be related primarily to our incomplete understanding of the pathogenic mechanisms underlying PD, and excessive reliance on data from toxin-based animal models to judge which agents should be selected for clinical trials. Restricted resources inevitably mean that difficult compromises must be made in terms of trial design, and reliable estimation of efficacy is further hampered by the absence of validated biomarkers of disease progression. Drug development in PD dementia has been mostly unsuccessful; however, emerging biochemical, genetic and pathological evidence suggests a link between tau and amyloid-β deposition and cognitive decline in PD, potentially opening up new possibilities for therapeutic intervention. This Review discusses the most important 'druggable' disease mechanisms in PD, as well as the most-promising drugs that are being evaluated for their potential efficiency in treatment of motor and cognitive impairments in PD

Numerical Comparison of Cusum and Shiryaev-Roberts Procedures for Detecting Changes in Distributions

The CUSUM procedure is known to be optimal for detecting a change in distribution under a minimax scenario, whereas the Shiryaev-Roberts procedure is optimal for detecting a change that occurs at a distant time horizon. As a simpler alternative to the conventional Monte Carlo approach, we propose a numerical method for the systematic comparison of the two detection schemes in both settings, i.e., minimax and for detecting changes that occur in the distant future. Our goal is accomplished by deriving a set of exact integral equations for the performance metrics, which are then solved numerically. We present detailed numerical results for the problem of detecting a change in the mean of a Gaussian sequence, which show that the difference between the two procedures is significant only when detecting small changes.Comment: 21 pages, 8 figures, to appear in Communications in Statistics - Theory and Method